Inkoto Liyongo Clément
Research Subjects
Research Interests
Inkoto Liyongo Clément has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Koto-Te-Nyiwa Ngbolua
Université de Kinshasa
3 shared publications - Colette Ashande Masengo
Institut Supérieur des Techniques Médicales de KKinshasa
2 shared publications - Damien Sha-Tshibey Tshibangu
Department of Chemistry, Faculty of Sciences, University of Kinshasa
2 shared publications - Dorothée D. Tshilanda
Faculté des Sciences, Université de Kinshasa, B.P. 190 Kinshasa XI, DR Congo
2 shared publications - Pius Tshimankinda Mpiana
Conseil Scientifique National
2 shared publications - Adrien Tuwisana Masunda1 shared publication
Latest Publications
- Open Access
- 27 September 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 8
WO₃ nanoparticles: Synthesis and recent advances in their applications for radiotherapy and radioprotection
- 27 September 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 8
Open AccessWO₃ nanoparticles: Synthesis and recent advances in their applications for radiotherapy and radioprotection
- Open Access
- 16 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (2) , 265-273
Glucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence
Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.
- 16 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (2) , 265-273
Open AccessGlucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence
Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.
- Open Access
- 13 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (3) , 335-342
Mini-review on the phyto-chemistry, pharmacology and toxicology of Cola nitida (Vent.) Schott & Endl. (Malvaceae): A medically interesting bio-resource of multiple purposes in Africa
The purpose of this mini-review was to summarize and update knowledge on the phytochemistry, pharmacology, and toxicity of Cola nitida, with the view of providing baseline data for herbal drug formulation. In January 2021, a non-exhaustive online search of relevant articles was carried out on the phytochemistry, pharmacology, and toxicology of C. nitida from scientifically well-established databases such as Science Direct, PubMed, Web of Science, Scopus, Google Scholar, and SciELO. The plant's scientific name as well as phytochemistry, pharmacology, pharmacognosy, bioactivity and toxicology were used as keywords. The chemical structures of the compounds isolated from this plant were drawn using ChemBioDraw Ultra 12.0 software. A literature survey has revealed that C. nitida is highly appreciated by African populations in various cultures, especially in West Africa. Phytochemical analyses showed that C. nitida contains interesting compounds like catechin, caffeine, epicatechin, polyphenols, alkaloids, tannins, saponins, bromelain, cardenolides, proanthocyanidins, triterpenes, glycosides, flavonoids, anthraquinones, steroids, anthocyanins, glycosides, alkaloids, etc. The presence of these phyto-compounds in the investigated plant species justifies its used as an antimicrobial, anti-malarial, anti-inflammatory, anti-diabetic, anti-coagulant agent. Thus, C. nitida could be used as a raw material for manufacturing efficient medication against various diseases, including sickle cell disease.
- 13 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (3) , 335-342
Open AccessMini-review on the phyto-chemistry, pharmacology and toxicology of Cola nitida (Vent.) Schott & Endl. (Malvaceae): A medically interesting bio-resource of multiple purposes in Africa
The purpose of this mini-review was to summarize and update knowledge on the phytochemistry, pharmacology, and toxicity of Cola nitida, with the view of providing baseline data for herbal drug formulation. In January 2021, a non-exhaustive online search of relevant articles was carried out on the phytochemistry, pharmacology, and toxicology of C. nitida from scientifically well-established databases such as Science Direct, PubMed, Web of Science, Scopus, Google Scholar, and SciELO. The plant's scientific name as well as phytochemistry, pharmacology, pharmacognosy, bioactivity and toxicology were used as keywords. The chemical structures of the compounds isolated from this plant were drawn using ChemBioDraw Ultra 12.0 software. A literature survey has revealed that C. nitida is highly appreciated by African populations in various cultures, especially in West Africa. Phytochemical analyses showed that C. nitida contains interesting compounds like catechin, caffeine, epicatechin, polyphenols, alkaloids, tannins, saponins, bromelain, cardenolides, proanthocyanidins, triterpenes, glycosides, flavonoids, anthraquinones, steroids, anthocyanins, glycosides, alkaloids, etc. The presence of these phyto-compounds in the investigated plant species justifies its used as an antimicrobial, anti-malarial, anti-inflammatory, anti-diabetic, anti-coagulant agent. Thus, C. nitida could be used as a raw material for manufacturing efficient medication against various diseases, including sickle cell disease.
- Open Access
- 23 January 2021
- Published by Sumerianz Publication in Sumerianz Journal of Biotechnology
- No. 41,p. 16-21
Mineral Composition of Medicinal Plants Traditionally Used in the Management of Sickle Cell Disease in the Kwilu Province (Congo-Kinshasa)
Sumerianz is a publisher of peer reviewed international journals. Our aim is to promote high quality genuine research from the whole world.
- 23 January 2021
- Published by Sumerianz Publication in Sumerianz Journal of Biotechnology
- No. 41,p. 16-21
Open AccessMineral Composition of Medicinal Plants Traditionally Used in the Management of Sickle Cell Disease in the Kwilu Province (Congo-Kinshasa)
Sumerianz is a publisher of peer reviewed international journals. Our aim is to promote high quality genuine research from the whole world.